Veterinary Medicines

PANCLOSTIL ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΓΙΑ ΠΡΟΒΑΤΑ

Authorised
  • Clostridium chauvoei, Inactivated
  • Clostridium tetani, toxoid
  • Clostridium septicum, toxoid
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium perfringens, type C, beta toxoid
  • Clostridium perfringens, type A, alpha toxoid
Download as PDF

Product identification

Medicine name:
PANCLOSTIL ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ ΓΙΑ ΠΡΟΒΑΤΑ
Active substance:
  • Clostridium chauvoei, Inactivated
  • Clostridium tetani, toxoid
  • Clostridium septicum, toxoid
  • Clostridium perfringens, type D, epsilon toxoid
  • Clostridium perfringens, type C, beta toxoid
  • Clostridium perfringens, type A, alpha toxoid
Target species:
  • Sheep
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Clostridium chauvoei, Inactivated
    100.00
    Percentage protective dose
    /
    1.00
    millilitre(s)
  • Clostridium tetani, toxoid
    2.50
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium septicum, toxoid
    2.50
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type D, epsilon toxoid
    5.00
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type C, beta toxoid
    10.00
    international unit(s)
    /
    1.00
    millilitre(s)
  • Clostridium perfringens, type A, alpha toxoid
    2.00
    international unit(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Sheep
      • Meat and offal, milk
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI04AB01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Greece
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Complete application (stand-alone)
Marketing authorisation holder:
  • Ceva Hellas LLC
Marketing authorisation date:
Manufacturing sites for batch release:
  • CEVA-Phylaxia Zrt.
  • CZ Vaccines S.A.U.
Responsible authority:
  • National Organization For Medicines
Authorisation number:
  • 24250/10-03-2022/K-0063001
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 16/09/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Greek (PDF)
Published on: 16/09/2024
Download